CL2024002837A1 - Inmunosupresión específica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis múltiple y la enfermedad por anticuerpos mog - Google Patents

Inmunosupresión específica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis múltiple y la enfermedad por anticuerpos mog

Info

Publication number
CL2024002837A1
CL2024002837A1 CL2024002837A CL2024002837A CL2024002837A1 CL 2024002837 A1 CL2024002837 A1 CL 2024002837A1 CL 2024002837 A CL2024002837 A CL 2024002837A CL 2024002837 A CL2024002837 A CL 2024002837A CL 2024002837 A1 CL2024002837 A1 CL 2024002837A1
Authority
CL
Chile
Prior art keywords
multiple sclerosis
mog antibody
mhc
novel treatment
antibody disease
Prior art date
Application number
CL2024002837A
Other languages
English (en)
Spanish (es)
Inventor
Wischhusen Jörg
Bruttel Valentin
Brünnert Daniela
Ahsan Fadhil
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Publication of CL2024002837A1 publication Critical patent/CL2024002837A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2024002837A 2022-03-24 2024-09-23 Inmunosupresión específica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis múltiple y la enfermedad por anticuerpos mog CL2024002837A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22164122 2022-03-24

Publications (1)

Publication Number Publication Date
CL2024002837A1 true CL2024002837A1 (es) 2025-02-21

Family

ID=81389016

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002837A CL2024002837A1 (es) 2022-03-24 2024-09-23 Inmunosupresión específica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis múltiple y la enfermedad por anticuerpos mog

Country Status (12)

Country Link
US (1) US20250222083A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499676A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513720A (cg-RX-API-DMAC7.html)
KR (1) KR20240162578A (cg-RX-API-DMAC7.html)
CN (1) CN118922435A (cg-RX-API-DMAC7.html)
AU (1) AU2023240382A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255287A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002837A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013220A2 (cg-RX-API-DMAC7.html)
IL (1) IL315510A (cg-RX-API-DMAC7.html)
MX (1) MX2024011667A (cg-RX-API-DMAC7.html)
WO (1) WO2023180546A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202519540A (zh) * 2023-09-22 2025-05-16 德國符茲堡大學 MHC Ib媒介之髓磷脂特異性免疫抑制作為用於多發性硬化症及MOG抗體疾病之新穎治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063959A1 (en) 2017-05-23 2018-11-29 Julius-Maximilians-Universitat Wurzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
US11464840B2 (en) * 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers

Also Published As

Publication number Publication date
WO2023180546A1 (en) 2023-09-28
CA3255287A1 (en) 2023-09-28
US20250222083A1 (en) 2025-07-10
IL315510A (en) 2024-11-01
AU2023240382A1 (en) 2024-11-14
WO2023180546A8 (en) 2024-10-17
JP2025513720A (ja) 2025-04-30
EP4499676A1 (en) 2025-02-05
CO2024013220A2 (es) 2024-10-31
MX2024011667A (es) 2024-09-27
KR20240162578A (ko) 2024-11-15
CN118922435A (zh) 2024-11-08

Similar Documents

Publication Publication Date Title
CO2023018231A2 (es) Restos de administración terapéutica novedosos y usos de estos
CO2024013220A2 (es) Inmunosupresión específica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis múltiple y la enfermedad por anticuerpos mog
AR087615A1 (es) Moleculas biespecificas de union a antigeno
CL2024001738A1 (es) Vacunas peptídicas
UY28289A1 (es) Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diasnostico y tratamiento de tumores
AR115721A1 (es) Anticuerpos que comprenden un polipéptido insertado en la región marco 3
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
CO2020013221A2 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
CO2022018347A2 (es) Cisteína proteasa
AR101871A1 (es) Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos
CO2024012329A2 (es) Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson
BR112022003633A2 (pt) Métodos para produção de arginase 1 recombinante humana e usos da mesma
CO2025009946A2 (es) Proteínas de unión al antígeno anti-tnfr2 y sus usos
CO2024012332A2 (es) Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo
CO2024003578A2 (es) Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
CO2022011195A2 (es) Composiciones y métodos para aumentar o mejorar la transducción de vectores de terapia génica y para eliminar o reducir inmunoglobulinas
AR126749A1 (es) Tratamiento de la dermatitis atópica
AR122659A1 (es) Anticuerpos biespecíficos para linfocitos t activados por proteasa
CO2026004947A2 (es) Proteínas de unión al receptor de transferrina y usos de estas
MX2024014378A (es) Proteinas de fusion que comprenden un agonista mejorado del receptor glp-1 y sus usos
PE20252164A1 (es) Conjugado de anticuerpo-farmaco anti-her2 para el tratamiento del cancer de mama
CL2025002824A1 (es) Nueva molécula de unión
BR112021021210A2 (pt) Conjunto de polipeptídeos, método para gerar um polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico, segundo polipeptídeo precursor heterodimérico e composição farmacêutica
CO2024012945A2 (es) Inmunosupresión específica del antígeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1
CO2025011125A2 (es) Conjugados anticuerpo-fármaco anti-cd70